פתחים סמויים מהעין

Discovery Laboratories upgraded to Outperform at Harris Nesbitt (6.47 )

Harris Nesbitt upgrades DSCO to Outperform from Neutral after the European Commission granted Orphan Drug Status to Discovery's replacement surfactant Surfaxin for the treatment of R.D.S. Firm says that this decision, coupled with a decision by the NEJM to review the Surfaxin pivotal trial, provide confidence that Surfaxin is generally viewed as an exciting medical breakthrough -- key elements in the drug's approval and commercial launch. Target is $15.